Posted on by listeningmoon

Summary of “Quality of Decision Making in Radiation Oncology”

Radiation plays an important role in cancer treatment, but deciding when to use radiation, what type to use, and what dose to give requires careful clinical judgment. Many factors can influence a physician’s decision-making. The authors’ research particularly focuses on curative radiation therapy, including dose schedules and newer technologies.

Some radiation therapies have strong clinical trial evidence, but they may not always apply well to real-world patients. This is because patient characteristics are an important factor in radiation treatment outcomes. Different patients have different backgrounds, such as age, sex, frailty, and comorbidities. In addition, patients’ sociodemographic factors are also very important in radiotherapy decision-making. For example, insurance coverage, financial situation, and distance from the treatment center can all influence whether a patient receives radiotherapy or a specific dose schedule.

As for dose and schedule in radiotherapy, the authors mainly reviewed breast cancer and prostate cancer studies, comparing hypofractionation (higher doses over fewer treatment sessions) and standard fractionation (lower doses given once a day over several weeks). The authors reviewed clinical data from multiple countries, including India, Canada, Denmark, China, Australia, and England, and concluded that higher-dose schedules can achieve similar outcomes to standard schedules, while also saving patients time and money and reducing healthcare system resource use.

Finally, the authors reviewed new technologies in radiotherapy, such as intensity-modulated radiotherapy (IMRT), magnetic resonance imaging (MRI)-guided radiotherapy, stereotactic ablative body radiotherapy (SABR), and proton/charged-particle therapy. Older radiation therapy uses CT scans to locate the tumor and delivers high-energy X-rays from a few fixed directions. Although effective, it exposes more nearby healthy tissue to radiation compared with newer techniques. Unlike older radiation therapy, MRI uses live MRI imaging to help target a tumor more accurately while treatment is happening, IMRT uses computer-guided radiation beams from multiple directions to target the tumor more precisely and better protect nearby healthy tissue. SABR uses highly precise imaging and delivers a few high-dose treatments instead of many smaller ones. Proton and charged-particle therapy use tiny, charged particles instead of X-rays. These particles stop more precisely at the tumor, reducing radiation exposure to surrounding healthy tissues.

Understanding different types of radiotherapy, clinical trial evidence on dose schedules, and new technologies can help doctors, patients, and healthcare systems make more appropriate treatment decisions. It can help avoid both over-treatment (therapeutic enthusiasm) and under-treatment (therapeutic nihilism) and improve both survival and quality of life.

Although newer technologies are more precise and better at protecting healthy tissues, the equipment is expensive, and many low-income countries or regions cannot afford them. For patients in those areas, traditional radiotherapy may still be the only available option.

References

Vinod SK, Merie R, Harden S. Quality of decision making in radiation oncology. Clin Oncol (R Coll Radiol). 2025;38:103523. doi:10.1016/j.clon.2024.02.001

Posted on by listeningmoon

Summary of “Survival outcomes associated with prolonged pembrolizumab after definitive chemoradiation for non–small cell lung cancer”

Pembrolizumab is a cancer drug that boosts the immune system, and when used with chemotherapy and radiation therapy, it can improve survival in patients with non-small cell lung cancer. However, it is still unclear how long the patients with non–small cell lung cancer should continue taking pembrolizumab after completing chemotherapy and radiation therapy. While clinical trials exist, patients in everyday clinical practice may have different outcomes because of side effects, cancer progression, personal preferences, access to care, and doctors’ treatment decisions.

The researchers conducted this study to evaluate how long patients lived and how often they used healthcare services while taking pembrolizumab. They retrieved data from the U.S. Collaborative Network called TriNetX, a de-identified electronic health record database covering multiple healthcare organizations.

On January 27, 2026, the researchers identified adult patients and divided them into two groups: 914 patients in the long-term pembrolizumab exposure group and 471 patients in the short-term group. After matching patients with similar characteristics, the final cohort included 899 patients in the long-term group and 458 in the short-term group. The long-term group received pembrolizumab for approximately 9–14 months, while the short-term group received it for up to 6 months. All patients had at least one year of follow-up, and chemoradiation was completed within three months before or at the start of treatment.

The researchers found that the long-term exposure group had a lower risk of death compared with the short-term group. There were 166 deaths among 448 patients (37.1%) in the long-term group and 207 deaths among 446 patients (46.4%) in the short-term group. On average, patients in the long-term group lived much longer (1505 days compared with 791 days). Use of healthcare services during treatment was similar between the two groups, with no significant difference observed.

These findings suggest that longer treatment with pembrolizumab is associated with improved survival in patients with non–small cell lung cancer treated with chemoradiation. It may reduce mortality and extend survival compared with shorter treatment duration, while maintaining similar healthcare utilization.

However, pembrolizumab cannot be assumed to benefit all patients equally, as outcomes may be influenced by differences in the cancer itself, response to therapy, treatment tolerance, patient frailty, clinician decision-making, access to care, and follow-up patterns. Another limitation is a survival-related bias, where patients in the long-term group had to survive long enough to receive additional treatment, which may make that group appear to have better outcomes. A further limitation is that other patient characteristics that were not fully accounted for may have affected both treatment duration and survival.

Reference

Homeniuk A, Syed A, Atrash A. Survival outcomes associated with prolonged pembrolizumab after definitive chemoradiation for non–small cell lung cancer. Clin Oncol (R Coll Radiol). Published online 2026. doi:10.1016/j.clon.2026.104227